Corporate Vice President and Interim Chief Financial Officer
Emma Reeve is a global finance executive who has focused on healthcare for more than 20 years through roles at pharmaceutical, medical device and biopharmaceutical service companies. She joined PAREXEL in September 2014 as a Corporate Vice President and Controller. Leading a team of 300 people in this position, she has responsibility for SEC reporting, Investor Relations, Financial Planning and Analysis, Shared Service Centers and Process improvement. Ms. Reeve will continue in this role while serving as Interim Chief Financial Officer.
Before joining PAREXEL, Ms. Reeve held senior financial roles at major pharmaceutical companies, including Novartis, Merck and Bristol-Myers Squibb. She has also held the Chief Financial Officer role at two development-stage biotechnology companies, Aton Pharma and Inotek Pharmaceuticals. At Aton Pharma, Ms. Reeve was a lead member of the team that sold the company to Merck in a ground-breaking deal. At Inotek Pharmaceuticals, she successfully raised private equity financing for the company in a difficult capital market.
In addition to finance, Ms. Reeve has held senior positions in marketing, supply chain management and research operations. She has worked in a number of countries with roles at the local, regional and corporate levels to gain a deep understanding of the biopharmaceutical industry. Her strengths lie in building and leading teams and managing businesses to value-creation milestones. She has robust experience in business transformation and change management.
Ms. Reeve has a degree in Computing Science from the Imperial College of Science & Technology, University of London and is a Chartered Accountant.